A Phase 2/3 interventional study of AZD1722 and Placebo in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by Ardelyx · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.
Among the 11 studies testing tenapanor in Constipation, this one is the 4th largest by enrollment, is the only one that started in 2013, is the only one in phase 2/3, and was the 2nd registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:
Ardelyx · Sites in United States
Ages 18–80
Cedar Valley Digestive Health Center · Sites in United States
Ages 50–89
Ardelyx · Sites in United States
Ages 6–18
By country, each count listing its studies:
tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8
First in 2011; this study’s year is marked. 1 started in 2013.
This study's enrollment of 356 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 186 across the 11 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Ardelyx has 9 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
2 of the studies testing tenapanor in Constipation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07382167Phase 3ArdelyxA 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | 2027-02-26 |
| NCT06460038Cedar Valley Digestive Health CenterTenapanor in Synucleinopathy-Related Constipation | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing tenapanor in Constipation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III criteria and who have active disease as determined during a two-week screening period. Subjects who qualify and are randomized into the study will receive 5, 20, or 50 mg of AZD1722 BID or placebo BID for 12 consecutive weeks. At the end of this treatment period, subjects will be followed for an additional 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD1722
Drug: AZD1722
AZD1722
Drug: AZD1722
AZD1722
Drug: AZD1722
Drug: Placebo
Also known as: RDX5791, Tenapanor
Percent Complete Spontaneous Bowel Movement Responders vs Placebo
Weekly complete spontaneous bowel movement resaponders defined as an increase of one or more bowel movement per week from baseline for 6 of the 12 weeks
Time frame: 12 weeks
| Milestone | 5 mg BID | 20 mg BID | 50 mg BID | Placebo |
|---|---|---|---|---|
| Started | 88 | 89 | 89 | 90 |
| Completed | 69 | 77 | 78 | 80 |
| Not completed | 19 | 12 | 11 | 10 |
| Withdrew: Adverse event | 8 | 6 | 3 | 3 |
| Withdrew: Withdrawal by subject | 5 | 3 | 0 | 4 |
| Withdrew: Lost to follow-up | 2 | 1 | 5 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 2 | 1 |
| Withdrew: Non compliance to treatment | 1 | 2 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 1 |
Weekly complete spontaneous bowel movement resaponders defined as an increase of one or more bowel movement per week from baseline for 6 of the 12 weeks
| Participants | 5 mg BID | 20 mg BID | 50 mg BID | Placebo |
|---|---|---|---|---|
| Percent Complete Spontaneous Bowel Movement Responders vs Placebo | 35 | 38 | 51 | 30 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg BID | — | 2/88 (2.3%) | 10/88 (11.4%) |
| 20 mg BID | — | 1/89 (1.1%) | 13/89 (14.6%) |
| 50 mg BID | — | 0/89 (0%) | 15/89 (16.9%) |
| Placebo | — | 1/90 (1.1%) | 4/90 (4.4%) |
| Event | 5 mg BID | 20 mg BID | 50 mg BID | Placebo |
|---|---|---|---|---|
| Laryngeal neoplasmRespiratory, thoracic and mediastinal disorders | 1/88 | 0/89 | 0/89 | 0/90 |
| Urinary Tract InfectionInfections and infestations | 1/88 | 0/89 | 0/89 | 0/90 |
| small intestinal obstructionGastrointestinal disorders | 0/88 | 1/89 | 0/89 | 0/90 |
| OsteomyelitisMusculoskeletal and connective tissue disorders | 0/88 | 0/89 | 0/89 | 1/90 |
| Event | 5 mg BID | 20 mg BID | 50 mg BID | Placebo |
|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 7/88 | 11/89 | 10/89 | 0/90 |
| Urinary Tract InfectionInfections and infestations | 3/88 | 2/89 | 5/89 | 4/90 |
Safety Analysis Set
| Age, Categorical(Participants) | 5 mg BID | 20 mg BID | 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 84 | 82 | 84 | 81 | 331 |
| >=65 years | 4 | 7 | 5 | 9 | 25 |
| Sex: Female, Male(Participants) | 5 mg BID | 20 mg BID | 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|
| Female | 76 | 77 | 79 | 77 | 309 |
| Male | 12 | 12 | 10 | 13 | 47 |
| Ethnicity (NIH/OMB)(Participants) | 5 mg BID | 20 mg BID | 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 22 | 30 | 24 | 29 | 105 |
| Not Hispanic or Latino | 66 | 59 | 65 | 61 | 251 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 5 mg BID | 20 mg BID | 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 2 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 18 | 19 | 17 | 22 | 76 |
| White | 69 | 67 | 69 | 65 | 270 |
| More than one race | 1 | 0 | 1 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| BMI(kg/m^2) | 5 mg BID | 20 mg BID | 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 29.5 ± 5.65 | 28.5 ± 5.27 | 28.3 ± 4.87 | 28.7 ± 5.63 | 28.7 ± 5.36 |
The record gives a start of Aug 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenapanor